Experimental antibody takes on tough bile duct cancers
NCT ID NCT05297903
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called XmAb20717 in 27 adults with advanced biliary tract cancers (bile duct or gallbladder cancer) that worsened after standard chemotherapy. The drug is a bispecific antibody designed to activate the immune system against cancer by blocking two checkpoints (PD-1 and CTLA-4). Researchers are measuring how many patients' tumors shrink or disappear, and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XmAb20717 (a bispecific antibody that targets two immune checkpoints, PD-1 and CTLA-4)
What this could lead to
If successful, this could provide a new treatment option for patients with advanced biliary tract cancers who have run out of standard chemotherapy options.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to all patients. The drug may cause immune-related side effects and may not shrink tumors in everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States